Pfizer Inc. (PFE)
Why Pfizer sold its $3 billion stake in Haleon
Pfizer's decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each, reduced Pfizer's ownership in the British consumer healthcare giant to 7.3%.
Pfizer to further reduce stake in Haleon through share sale
Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building process targeting institutional investors. Currently holding 15% of the Panadol maker, Pfizer expects to reduce its interest to about 7.3 per cent upon completion.
Pfizer Sells 700 Million Haleon Shares for $3 Billion
The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
Pfizer (PFE) reachead $26.41 at the closing of the latest trading day, reflecting a -1.46% change compared to its last close.
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A. Cohen's former hedge fund, SAC Capital Management.
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. PFE Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.”
Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer intends to sell about 700 million ordinary shares in Haleon , cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.
Pfizer CEO Albert Bourla: Our 2025 focus is on pipeline
Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu is the next pandemic, and more.
Pfizer Inc. (PFE) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 12:45 PM ET Company Participants Albert Bourla - Chairman & Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody.
Pfizer going 'all in' on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Exeuctive Officer Albert Bourla said at the JPMorgan Healthcare conference on Monday.
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
The 'Dogs of the Dow' strategy can be applied to Pfizer in 2025 for its 6.4% dividend and a former 'Dog.'. PFE's growth recovery, historical cheap valuation, and positive investment sentiment make it a strong candidate for high-yield income portfolios. Insider buying and positive net money flow indicate confidence in the Company's stability and potential for a 20% yield through dividends and covered calls.
